Search PubMed⌕ Search

Biomedical subjects

R McBride

Publications and source records attributed to R McBride.

At least 37 records · Page 2Linked to original sources
PubMed1996

Biochemical markers of alcohol abuse.

Excessive alcohol consumption is a major health problem in the UK leading to both serious morbidity and mortality. This study compared newer potential biochemical markers of excessive alcohol consumption [carbohydrate-deficient transferrin (CDT), mitochondrial AST (mAST) and alpha glutathione-s-transferase (alpha-GST)] with conventional markers (AST, ALT, GGT, MCV). Patients (n = 85) were enrolled in the study and subdivided into several groups on the basis of alcohol consumption. Patients with non-alcoholic liver disease (NALD) (n = 40) were also enrolled. All the markers, with the exception of the ratio mAST/total AST were significantly higher in heavy drinkers/alcoholics compared to teetotallers/social drinkers (p < 0.05). mAST and AST/ALT ratio were significantly higher in alcoholics compared to NALD (p < 0.01), whereas ALT was higher in the NALD group (p < 0.05). Multivariate discriminant function analysis (Wilks method) demonstrated that the logarithmic functions of AST/ALT ratio and mAST could correctly classify 87.9% of cases into either the alcoholic or NALD groups. ROC plot analysis showed that AST, mAST and GGT were the best markers at distinguishing heavy consumption of alcohol from lesser levels and that AST/ALT ratio and mAST were the best in distinguishing alcoholics from NALD. In conclusion, none of the newer biochemical markers, with the exception of mAST, offers any major advantage over the conventional markers.

Adult↗
PubMed1996

The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.

BACKGROUND: Care of patients with ventricular arrhythmia after myocardial infarction requires careful nursing management, including assisting with arrhythmia monitoring and testing. Because ventricular premature depolarization is a known risk factor for sudden cardiac death, it was hypothesized that the suppression of asymptomatic or mildly symptomatic ventricular premature depolarization would improve survival in these patients. OBJECTIVE: To review the Cardiac Arrhythmia Suppression Trial findings and provide implications for nursing practice for patients after myocardial infarction. METHODS: The Cardiac Arrhythmia Suppression Trial was a multicenter, randomized, placebo-controlled trial designed to determine whether the suppression of ventricular premature depolarizations in postmyocardial infarction patients would improve survival. Three class I antiarrhythmic drugs were used: encainide, flecainide, or moricizine. Patients for whom the drug suppressed their arrhythmia 80% or more were randomly assigned to that drug and dose or its matching placebo and were followed every 4 months (main study). Patients with 1% to 79% suppression were randomly assigned to the drug or its placebo that best treated their arrhythmia and followed every 4 months. RESULTS: Suppression of asymptomatic or mildly symptomatic ventricular premature depolarization in patients using encainide, flecainide, or moricizine failed to improve patient survival and was even harmful in some cases. CONCLUSIONS: Our results showed that in the absence of effective antiarrhythmic drug therapy, supportive nursing care and arrhythmia monitoring is important until appropriate therapy for the management of these arrhythmias in patients who have had a myocardial infarction can be found. Clinical trials are essential to provide an evaluation of therapies and direction for further studies, as well as a basis for practicing clinicians.

Aged↗
PubMed1995

Prospective evaluation of complications associated with percutaneous intraaortic balloon counterpulsation.

In summary, current, prospective experience with 691 consecutive patients revealed that female gender, peripheral vascular disease, cardiac index, and diabetes were the only independent predictors of risk after percutaneous IAB insertion. Neither sheathless insertion nor smaller IAB catheter size was associated with a lower complication rate. There may be a threshold of catheter size associated with a dramatic reduction in complications. If that exists, it has not yet been reached.

Aged↗
PubMed1995

Toward vital status sweeps: a case history in sequential monitoring.

We use data from the Cardiac Arrhythmia Suppression Trial (CAST) to demonstrate the sensitivity of sequential monitoring to the timeliness of survival data. In CAST vital status sweeps were not routinely performed prior to the times of sequential analysis. Examination of the delay between death and reporting of death shows that the change in the time of sequential analysis by even as few as several months can have dramatic impact on the results of the sequential analysis.

Anti-Arrhythmia Agents↗
PubMed1995

Pilot prospective evaluation of counterpulsation with different intra-aortic balloon volumes on cardiac performance in humans.

UNLABELLED: Smaller intra-aortic balloons (IAB) may minimize peripheral vascular complications. To determine the influence of different IAB volumes on cardiac performance, we studied 20 hemodynamically stable patients on IAB counterpulsation. Variables were measured with either a 40cc or 32cc IAB displacement, at an assist ratio of 1:1 or 1:8: Heart rate, Ao and PA pressures, and Fick cardiac output. By echo-Doppler, the velocity time integral (VTI) across the LV outflow tract, a measure of stroke volume was also calculated. The mean age was 60 yr (range 18-77), height 5'6" (5'2"-5'11"), and body surface area 1.9M2 (1.5-2.3). Results presented as mean values were: [table: see text] *P < 0.005 1:1 vs 1:8 for both 40 and 32cc IAB. CONCLUSION: IAB pumping at 1:1 with either 40 cc or 32 cc volume displacement yields similar degrees of improvement in cardiac performance. A larger cohort is required to determine if smaller balloons may decrease complications without compromising efficacy.

Adolescent↗
PubMed1995

Tympanic membrane thermometry in the care of out-of-hospital patients.

STUDY OBJECTIVES: To determine the effectiveness of tympanic membrane (TM) thermometry in the out-of-hospital setting and to characterize the patients with abnormal out-of-hospital temperatures. DESIGN: Prospective, randomized, single-month study. SETTING: Inner city. PARTICIPANTS: Subjects transported by ambulance for whom consent was obtainable. RESULTS: TM probes set to rectal equivalent were assigned to three of the ambulance units of the local health department on randomly selected shifts during August 1992, one half at night and one half during the day. Simultaneous left and right ear temperatures at the scene and at the hospital, ambient temperatures, and patient's hospital temperatures were recorded. Other data recorded included each patient's mental status, activity level, and environment temperature. Paramedics noted whether they suspected a temperature problem before using the probe and whether any treatment was directed toward the patient's temperature. Regression, bias analysis, and chi 2 testing were performed; P was considered significant if it was less than .05. Right and left ear TM temperatures were correlated both at the scene and at the hospital (r = .91 and .92, respectively). TM temperatures and hospital temperatures were also correlated (r = .83 for right ear and .78 for left ear). Evaluation of agreement indicated that TM and hospital methods were equal, with a bias of -0.55 degrees F for oral and +0.66 degrees F for rectal temperatures. Thirty-two subjects (17%) were hyperthermic at the scene; of these, 9 of 32 (28%) were suspected before use of the probe. The paramedics initially treated 5 of the 9 suspected to have a temperature-related problem before using the probe and none of the 23 who were not suspected before using the probe (chi 2, P < .001). CONCLUSION: The TM probe functioned well despite a month of vigorous handling. Temperature correlation with the gold standard and between ears was acceptable in this setting. Presence of the probe did not help with the management of hyperthermic patients in this study.

Adolescent↗
PubMed1993

Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

OBJECTIVES: This study was designed to compare the response of unstable angina and non-Q wave myocardial infarction during treatment with antithrombotic therapy. BACKGROUND: Antithrombotic therapy is beneficial in patients with these two coronary syndromes. METHODS: In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks. Admission cardiac enzyme analyses revealed unstable angina in 268 patients and non-Q wave myocardial infarction in 62. Given an event rate of about 25%, this study has a power of 80% to detect a 50% difference between the two groups. RESULTS: Patients with unstable angina and non-Q wave myocardial infarction were similar with regard to age, gender, coronary risk factors and prior antianginal medication. Primary end points at 12 weeks were recurrent ischemia, infarction and death. [table: see text] In the non-Q wave group, all infarctions and death occurred within the 1st week. CONCLUSIONS: Patients with unstable angina or non-Q wave myocardial infarction on antithrombotic therapy have a similar total number of ischemic events by 12 weeks. However, despite maximal medical therapy with antianginal and antithrombotic medication, patients with non-Q wave infarction have a significantly higher rate of reinfarction and death.

Adrenergic beta-Antagonists↗
PubMed1992

Smoking in patients with panic disorder.

We compared smoking prevalence in 217 patients with panic disorder with that in 217 age- and sex-matched control subjects who were obtained by telephone survey from the same neighborhoods. Data were obtained for current smoking habits and smoking status at either the onset of illness (patients) or 10 years previously (control subjects). Patients had been ill for 10.6 (SD = 10.0) years. Female patients with panic disorder had a significantly higher smoking prevalence at the onset of their illness than did control subjects 10 years previously (54% vs. 35%). The current smoking prevalence for female patients was also significantly higher than that of control subjects (40% vs. 25%). Male smoking rates did not differ between patients and control subjects. Caffeine use did not appear to explain these findings. These data suggest a link between smoking behavior and panic disorder in women.

Adult↗
PubMed1992

Single vs. double data entry in CAST.

An experiment was conducted to determine whether, using microcomputer-based data entry, double data entry (DE) significantly lowers data entry keying error rates when compared to single entry (SE). Clinical centers of the Cardiac Arrhythmia Suppression Trial (CAST) participated in a randomized crossover design experiment comparing SE and DE. A total of 42,278 data items (fields) were checked for consistency between the paper data form and the computer database. The overall error rate was 19 per 10,000 fields. Error rates were 22 and 15 per 10,000 fields for SE and DE, respectively; P = .09 by Poisson regression. DE took 37% longer than SE, costing each clinic approximately an extra 90 min per month.

Arrhythmias, Cardiac↗
PubMed1992

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

BACKGROUND AND OBJECTIVES: The relation between cardiac mortality and antiarrhythmic drug administration has not been fully determined. This relation was analyzed in 1,330 patients enrolled in the Stroke Prevention in Atrial Fibrillation Study, a randomized clinical trial comparing warfarin, aspirin and placebo for the prevention of ischemic stroke or systemic embolism in patients with nonvalvular atrial fibrillation. METHODS: Patients who received antiarrhythmic drug therapy for atrial fibrillation in this study were compared with patients not receiving antiarrhythmic agents. The relative risk of cardiac mortality, including arrhythmic death, in patients receiving antiarrhythmic drug therapy was determined and adjusted for other cardiac risk factors. RESULTS: In patients receiving antiarrhythmic drug therapy, cardiac mortality was increased 2.5-fold (p = 0.006, 95% confidence interval [CI] 1.3 to 4.9) and arrhythmic death was increased 2.6-fold (p = 0.02, 95% CI 1.2 to 5.6). Among patients with a history of congestive heart failure, those given antiarrhythmic medications had a relative risk of cardiac death of 4.7 (p less than 0.001, 95% CI 1.9 to 11.6) compared with that of patients not so treated; the relative risk of arrhythmic death in the treated group was 3.7 (p = 0.01, 95% CI 1.3 to 10.4). Patients without a history of congestive heart failure had no increased risk of cardiac mortality (relative risk 0.70, 95% CI 0.2 to 3.1) during antiarrhythmic drug therapy. After exclusion of 23 patients with documented ventricular arrhythmias and adjustment for other variables predictive of cardiac death, patients receiving antiarrhythmic drugs were not at increased risk of cardiac death or arrhythmic death. However, in patients with a history of heart failure who received antiarrhythmic drug therapy, the relative risk of cardiac death was 3.3 (p = 0.05, 95% CI 0.99 to 11.1) and that of arrhythmic death was 5.8 (p = 0.009, 95% CI 1.5 to 21.7) compared with the risk in patients not taking antiarrhythmic medications. CONCLUSIONS: Although antiarrhythmic drug therapy was not randomly determined in this trial, the data suggest that in patients with atrial fibrillation and a history of congestive heart failure, the risk of such therapy may outweigh the potential benefit of maintaining sinus rhythm.

Anti-Arrhythmia Agents↗
PubMed1991

Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.

The patient characteristics and outcomes were studied in the 318 patients who survived open label drug titration in the Cardiac Arrhythmia Suppression Trial (CAST) and who were not randomized to double-blind therapy and in 942 patients, who were randomized to double-blind placebo therapy. The patients randomized to placebo therapy had a lower total mortality or resuscitated cardiac arrest rate (4% vs. 8.5%). However, at baseline, nonrandomized patients were dissimilar from patients randomized to placebo in the following ways: older; lower left ventricular ejection fraction; greater use of digitalis, diuretic drugs and antihypertensive agents; lesser use of beta-adrenoceptor blocking agents and more frequent prior cardiac problems, including runs of ventricular tachycardia and left bundle branch block. A matched comparison that took these inequities into account showed no significant differences in mortality or rate of resuscitation from cardiac arrest between nonrandomized patients and clinically equivalent patients randomized to placebo. Cox regression analysis indicated that two factors significantly increased the hazard ratio for arrhythmic death or resuscitated cardiac arrest in the nonrandomized patients: female gender (4.7, p less than 0.05) and electrocardiographic events (ventricular tachycardia, proarrhythmia, widened QRS complex, heart block, bradycardia) during open label titration (7.0, p less than 0.005). However, some potentially important differences between men and women were not included in the Cox regression model. Of the nonrandomized patients, approximately 70% were not randomized because of lack of suppression of ventricular premature depolarizations or adverse events, or both, and the remaining 30% because of patient or private physician request with no indication of another reason.(ABSTRACT TRUNCATED AT 250 WORDS)

Anilides↗
PubMed1989

Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study).

The Cardiac Arrhythmia Pilot Study (CAPS) was a randomized, double-blind trial of antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine and placebo) in 502 patients with an ejection fraction greater than 0.20 and at least 10 ventricular premature complexes/hour, 6 to 60 days after acute myocardial infarction. Patients were followed for 1 year and the incidence of new or worsened congestive heart failure (CHF) was evaluated. Heart failure in the 1-year follow-up was gauged by the development (in order of increasing severity) of new symptoms (grade 1), the need for a change in therapy, including addition of digitalis, addition or increase of dose of diuretics or afterload reduction agents or discontinuation of beta-blocking agents (grade 2), or by hospitalization (grade 3). Sixty-one of 502 patients (12%) required hospitalization for CHF in the 1-year follow-up. One hundred five of 403 patients (26%) in the active treatment group and 18 of 99 patients (18%) in the placebo group (difference not significant) developed CHF requiring hospitalization or a change in therapy or both. Although patients with severely impaired ejection fraction were excluded, new or worsened CHF was common in follow-up during CAPS.

Anilides↗
PubMed1988

Design of clinical database management systems and associated software to facilitate medical statistical research.

Clinical databases are growing rapidly. The clinical database is heavily used for medical research in many settings. This paper discusses design features for medical databases that facilitate their use for research. The database management system should allow complex data structures, have a syntax-facilitating collection of longitudinal data, interface with major statistical software packages, allow an extensive data dictionary, conveniently merge files, facilitate archival documentation, have an associated data entry system that allows complex logical checking, and have coordinated mainframe and microcomputer software.

Biometry↗
PubMed1982

C2: a data base management system developed for the Coronary Artery Surgery Study (CASS) and other clinical studies.

For the Coronary Artery Surgery Study (CASS), large variable amounts of data on different form-types are collected on many different patients. In this paper, we describe C2, a "state-of-the-art" command-oriented data base system developed in response to the needs of maintaining a large complex data base and performing subsequent analyses on a large number of studies. C2 provides a friendly, interactive interface with the researcher as well as a powerful method for data extraction, data transformation, and the merging of files from the CASS data base.

Clinical Trials as Topic↗